# Phase 26 Closeout — Production-Path-Native Alpha Discovery & Validation

**Status:** target research COMPLETE; full phase-end closeout gate pending target-machine confirmation.  
**Frozen policy fingerprint:** `24e4f0e24d3e81dfc3dc572f0562337b2c156cd3ea22d6a7448b6ad6586016d2`

## Plain-English phase end

Phase 26 had one central job: determine whether a preregistered set of genuinely different, production-path-native strategy ideas could establish reliable historical trading edge after realistic costs and strict anti-overfitting controls.

The phase ran correctly, but the alpha hypothesis did not succeed. Across the frozen 24-candidate library, **no candidate survived the development-selection standard**. Because there were no selection survivors, there were no internal-validation finalists and no protected-confirmation candidates. Protected returns therefore remained completely unread, exactly as the methodology required.

This is not a software failure and it is not a reason to weaken the rules. It is valid negative scientific evidence. ATLAS still has no historically `SUPPORTED` strategy, so Phase 27's validated-alpha entry condition remains unsatisfied.

The practical consequence is that ATLAS's data, analytics, risk, execution-safety, and operator foundations remain useful and accepted, but they do not yet have a validated alpha source to turn into trade construction. The next research work must be a separately defined and preregistered alpha phase informed by this negative result. The frozen Phase 26 candidates or thresholds must not be tuned after seeing this outcome.

## Target evidence

Exact target-tested research head:

`8c9153c966ada116199fc45867bf5734efafeee4`

Target output:

- development usable observations: **21,483**;
- protected predictor observations: **1,096**;
- selection survivors: **0**;
- internal-validation finalists: **0**;
- protected-confirmed supported candidates: **0**;
- protected return rows read: **0**;
- independent validation: **PASS**;
- provider/broker/order/PAPER/LIVE activity: **0 / 0 / 0 / 0 / 0**;
- cumulative research evidence: **PASS**.

These row counts document the observed target evidence; they are not retrospective acceptance thresholds.

## Defects found and repaired before the valid target result

The final negative result was reached only after correcting implementation defects at their owning layers:

1. Phase 25 prerequisite recovery had accumulated redundant rebind/validator wrappers. The extra layer was removed and recovery returned to one authoritative recovery path plus the standard validator.
2. Phase 26 observation-report JSON persistence leaked NumPy/Pandas boolean scalars. The persistence boundary now requires native boolean checks and has regression coverage.
3. Phase 26 development research contained an impossible acceptance predicate (`protected_returns_read=False` inside an `all(checks.values())` map). The state/predicate confusion was removed and replaced by positive protected-blind invariants, with regression coverage.

No strategy definition, threshold, chronology, cost, bootstrap, multiplicity, robustness, or protected boundary was changed to obtain the final result.

## End-to-end anti-workaround audit

The required bounded audit is documented in `docs/phase26_end_to_end_anti_workaround_audit.md`.

Result: **PASS**. No acceptance-blocking workaround or parallel trading authority remains in the reviewed provider-to-execution critical path. Historical recovery code is bounded to provenance/rehydration and does not become routine promotion, risk, broker, PAPER, LIVE, or browser authority.

The closeout implementation also machine-checks the highest-risk conclusions, including a single raw broker-submit seam, no runtime imports of Phase 25 recovery authority, no automatic broker failover, no current browser provider-write/LIVE endpoint, and unchanged zero-supported Phase 23 strategy authority.

## Final acceptance gate

The final target-machine closeout command is:

```powershell
.\.venv\Scripts\python.exe scripts\run_phase26_closeout.py
```

It does **not** rerun the strategy search and does not expose new protected performance. It validates the already-produced target artifacts, independent-validation hashes, support overlay, protected-read state, zero external authority, and the anti-workaround audit.

Expected disposition for the observed evidence is **ACCEPTED_NEGATIVE**, with `phase27_entry_satisfied=False`.

Phase 26 must not be marked merged/accepted in the repository handoff until this final target closeout and exact-head CI both pass.
